ACOR - Acorda inks license deal with Asieris for pre-clinical drug

• Commercial-stage biopharmaceutical company Acorda Therapeutics ( NASDAQ: ACOR ) announced a license agreement with Chinese biotech Asieris Pharmaceuticals on Monday for the preclinical candidate, Nepicastat.
• Per the terms, the two companies will collaborate to develop Nepicastat, a small molecule drug for non-psychiatric indications and therapeutic uses.
• In return, Acorda ( ACOR ) is set to receive $500K of upfront payment, up to $7M of fees based on regulatory milestones, and a royalty on future net sales.
• Acorda ( ACOR ) U.S. subsidiary, Biotie Therapies, Inc., owns the rights for Nepicastat.
• Read: In June, the nano-cap ACRO stock surged in reaction to the launch of its inhalational Parkinson’s disease drug Inbrija in Germany. However, the company shares remain ~90% below the year-ago level, as indicated in this graph.

For further details see: